128 related articles for article (PubMed ID: 1302840)
1. [Bone tissue in patients with hyperprolactinemic hypogonadism].
Rozhinskaia LIa; Marova EI; Dzeranova LK; Rassokhin BM; Purtova GS; Goncharov NP; Mishchenko BP; Ilovaĭskaia IA
Probl Endokrinol (Mosk); 1992; 38(6):17-9. PubMed ID: 1302840
[TBL] [Abstract][Full Text] [Related]
2. The effects of hyperprolactinemia on bone and fat.
Shibli-Rahhal A; Schlechte J
Pituitary; 2009; 12(2):96-104. PubMed ID: 18338266
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia.
Schlechte J; Walkner L; Kathol M
J Clin Endocrinol Metab; 1992 Sep; 75(3):698-703. PubMed ID: 1517357
[TBL] [Abstract][Full Text] [Related]
4. Effects of prolactin and estrogen deficiency in amenorrheic bone loss.
Klibanski A; Biller BM; Rosenthal DI; Schoenfeld DA; Saxe V
J Clin Endocrinol Metab; 1988 Jul; 67(1):124-30. PubMed ID: 3379129
[TBL] [Abstract][Full Text] [Related]
5. [A study on bone metabolism in woman with hyperprolactinemia].
Fujimaki T; Kurabayashi T; Ootani T; Yamamoto Y; Yasuda M; Tanaka K
Nihon Sanka Fujinka Gakkai Zasshi; 1994 May; 46(5):423-8. PubMed ID: 8182302
[TBL] [Abstract][Full Text] [Related]
6. Plasma calcitonin, IGF-I levels and vertebral bone mineral density in hyperprolactinemic women during bromocriptine treatment.
Tørring O; Isberg B; Sjöberg HE; Bucht E; Hulting AL
Acta Endocrinol (Copenh); 1993 May; 128(5):423-7. PubMed ID: 8317189
[TBL] [Abstract][Full Text] [Related]
7. The role of cyclase activating (CAP) and cyclase inhibiting (CIP) parathormone fractions in the assessment of bone metabolism disturbances in women with hyperprolactinemia of various origin.
Zadrozna-Sliwka B; Bolanowski M; Jawiarczyk A; Kaluzny M; Syrycka J
Neuro Endocrinol Lett; 2008 Feb; 29(1):178-84. PubMed ID: 18283239
[TBL] [Abstract][Full Text] [Related]
8. Hyperprolactinemia and osteopenia.
Wardlaw SL; Bilezikian JP
J Clin Endocrinol Metab; 1992 Sep; 75(3):690-1. PubMed ID: 1517355
[No Abstract] [Full Text] [Related]
9. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.
Misra M; Papakostas GI; Klibanski A
J Clin Psychiatry; 2004 Dec; 65(12):1607-18; quiz 1590, 1760-1. PubMed ID: 15641865
[TBL] [Abstract][Full Text] [Related]
10. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males.
Di Somma C; Colao A; Di Sarno A; Klain M; Landi ML; Facciolli G; Pivonello R; Panza N; Salvatore M; Lombardi G
J Clin Endocrinol Metab; 1998 Mar; 83(3):807-13. PubMed ID: 9506732
[TBL] [Abstract][Full Text] [Related]
11. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
12. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea.
Schlechte J; el-Khoury G; Kathol M; Walkner L
J Clin Endocrinol Metab; 1987 May; 64(5):1021-6. PubMed ID: 3558723
[TBL] [Abstract][Full Text] [Related]
13. The effects of anorexia nervosa on bone metabolism in female adolescents.
Soyka LA; Grinspoon S; Levitsky LL; Herzog DB; Klibanski A
J Clin Endocrinol Metab; 1999 Dec; 84(12):4489-96. PubMed ID: 10599707
[TBL] [Abstract][Full Text] [Related]
14. Symptomatic osteoporosis in a man with hyperprolactinemic hypogonadism.
Jackson JA; Kleerekoper M; Parfitt AM
Ann Intern Med; 1986 Oct; 105(4):543-5. PubMed ID: 3752759
[TBL] [Abstract][Full Text] [Related]
15. Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio.
Seriwatanachai D; Thongchote K; Charoenphandhu N; Pandaranandaka J; Tudpor K; Teerapornpuntakit J; Suthiphongchai T; Krishnamra N
Bone; 2008 Mar; 42(3):535-46. PubMed ID: 18166509
[TBL] [Abstract][Full Text] [Related]
16. Bone density in amenorrheic women with and without hyperprolactinemia.
Schlechte JA; Sherman B; Martin R
J Clin Endocrinol Metab; 1983 Jun; 56(6):1120-3. PubMed ID: 6404918
[TBL] [Abstract][Full Text] [Related]
17. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism.
Greenspan SL; Oppenheim DS; Klibanski A
Ann Intern Med; 1989 Apr; 110(7):526-31. PubMed ID: 2923387
[TBL] [Abstract][Full Text] [Related]
18. Bones and Crohn's: estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density.
Klaus J; Reinshagen M; Adler G; Boehm B; von Tirpitz C
BMC Gastroenterol; 2008 Oct; 8():48. PubMed ID: 18947388
[TBL] [Abstract][Full Text] [Related]
19. The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats.
Kunimatsu T; Kimura J; Funabashi H; Inoue T; Seki T
Regul Toxicol Pharmacol; 2010 Dec; 58(3):360-8. PubMed ID: 20709132
[TBL] [Abstract][Full Text] [Related]
20. [Bone metabolism and fracture risk in anorexia nervosa].
Fernández Soto ML; González Jiménez A; Varsavsky M
Med Clin (Barc); 2010 Jul; 135(6):274-9. PubMed ID: 19631350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
